Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children68010.24287/1726-1708-2022-21-4-70-82ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИEfficacy and safety of low doses of olanzapine for the prevention of nausea and vomiting in children and adolescents receiving highly emetogenic chemotherapy. The interim results of a randomized trialЭффективность и безопасность малых доз оланзапина в профилактике тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию. Промежуточные результаты рандомизированного исследованияhttps://orcid.org/0000-0002-9054-5068ZhukovN. V.ЖуковН. В.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0001-9450-125XRabaevaL. L.РабаеваЛ. Л.
Russian Federation

Lilia L. Rabaeva, a pediatric oncologist at the Department of Adolescent Hematology/Oncology and Neuro-oncology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

117997, Moscow, Samory Mashela St., 1

Рабаева Лилия Леонидовна, врач-детский онколог отделения гематологии/онкологии старшего возраста и нейроонкологии

 117997, Москва, ул. Саморы Машела, 1

lilia.leonidovna.kazakova@gmail.comhttps://orcid.org/0000-0002-7461-0050LitvinovD. V.ЛитвиновД. В.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииN.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian FederationФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»2612202221470821701202317012023Copyright ©; 2022, «D. Rogachev NMRCPHOI»Copyright ©; 2022, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2022«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/680

International studies and the analysis of our own data demonstrate that the standard three-drug (5-HT3 receptor antagonist, aprepitant and dexamethasone) regimen used for the prevention of chemotherapy-induced nausea and vomiting (CINV) gives the possibility to achieve complete CINV control in less than 50% of children receiving highly emetogenic chemotherapy. According to the results of randomized trials in adult patients, the addition of low doses of olanzapine increases the efficacy of CINV prophylaxis. There is no data on the efficacy and safety of low-dose olanzapine used for the prevention of CINV in children. The aim of this study is to assess the efficacy and safety of adding low doses (0.07 mg/kg, maximum 5 mg) of olanzapine to the standard regimen used for CINV prophylaxis after highly emetogenic chemotherapy in children. The study includes patients receiving highly emetogenic chemotherapy at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, in case of which there are no other (except for chemotherapy) obvious reasons for nausea and vomiting and no contraindications for the use of olanzapine. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, and registered in the US National Library of Medicine clinical trials registry (http://clinicaltrials.gov), the identification number is NCT05346731. Patients were randomized in a 1:1 ratio and stratified (previously received highly emetogenic therapy or not; regimens with high doses of cisplatin/carboplatin and without it) to receive the first cycle of highly emetogenic chemotherapy with standard three-drug prophylaxis with the addition of low doses of olanzapine or without it. Then, the patients underwent a second similar cycle of highly emetogenic chemotherapy with a change in the antiemetic prophylaxis option (crossover). For the assessment of CINV, we used the Pediatric Nausea Assessment Tool (PeNAT). Adverse events were assessed using CTCAE v.5.0. This is an interim analysis and it was carried out in order to assess whether it was reasonable to continue the study. From March to August 2022, 31 patients were included in the study, the median age was 14 (5–18) years, the ratio of boys:girls was 15:16; all patients suffered from extracranial solid tumors. Considering crossover, 31 patients included in the study received 62 cycles of chemotherapy (31 cycles with olanzapine and 31 cycles without it). Out of 31 cycles of chemotherapy with standard three-drug prophylaxis, complete CINV control was achieved in 16 (52%) cases, out of 31 cycles with prophylaxis, which included low doses of olanzapine – in 24 (77%) cases (p = 0.027). Adverse events associated with olanzapine were quite common (sedation - 97%, weight gain -76%), but mild (< Grade III). According to the patient survey results, 30/31 (97%) patients preferred the regimen with olanzapine, and only 1 patient preferred neither of the regimens. The interim analysis of the study results shows that the addition of low doses of olanzapine significantly increases the efficacy of CINV prophylaxis in pediatric patients receiving highly emetogenic chemotherapy, is well tolerated, safe and preferred by the vast majority of patients. It is necessary to continue the study until the planned number of patients for the final analysis is included.

Согласно международным исследованиям и анализу собственных данных, стандартный трехкомпонентный (антагонист 5-НТ3-рецепторов, апрепитант и дексаметазон) режим профилактики тошноты и рвоты (ТИР) позволяет добиться их полного контроля менее чем у половины детей, получающих высокоэметогенную химиотерапию. По результатам рандомизированных исследований, добавление малых доз оланзапина у взрослых пациентов позволяет увеличить эффективность профилактики ТИР. Данные об эффективности и безопасности малых доз препарата при использовании для профилактики ТИР в детской популяции отсутствуют. Цель исследования – оценить эффективность и безопасность добавления малых доз (0,07 мг/кг, максимально 5 мг) оланзапина к стандартному режиму профилактики ТИР после высокоэметогенной химиотерапии у детей. В исследование включены пациенты, получающие высокоэметогенную химиотерапию в НМИЦ ДГОИ им. Дмитрия Рогачева, не имеющие других (кроме химиотерапии) очевидных причин для развития ТИР и противопоказаний для назначения оланзапина. Данное исследование одобрено независимым этическим комитетом и утверждено решением ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева, зарегистрировано в реестре клинических исследований Национальной медицинской библиотеки США (http://clinicaltrials.gov), идентификационный̆ номер NCT05346731. Пациенты рандомизировались в соотношении 1:1 со стратификацией (получали или не получали ранее высокоэметогенную терапию, использование режимов, содержащих и не содержащих высокие дозы цисплатина/карбоплатина) на проведение первого цикла высокоэметогенной химиотерапии со стандартной трехкомпонентной профилактикой с или без добавления малых доз оланзапина. Второй аналогичный курс высокоэметогенной химиотерапии проводился со сменой варианта противорвотной профилактики (перекрест). Для оценки ТИР использовались опросник и графическая шкала PeNAT. Оценка нежелательных явлений проведена с использованием критериев CTCAE v.5.0. Данный анализ является промежуточным и проводился в целях оценки целесообразности продолжения исследования. С марта по август 2022 г. в исследование был включен 31 пациент, медиана возраста составила 14 (5–18) лет, соотношение мальчики:девочки 15:16, все больные страдали солидными экстракраниальными опухолями. С учетом перекреста 31 пациент, включенный в исследование, получил 62 курса химиотерапии (31 цикл с оланзапином и 31 цикл без оланзапина). Из 31 цикла химиотерапии со стандартной трехкомпонентной профилактикой полного контроля ТИР удалось добиться в 16 (52%) случаях, из 31 цикла с профилактикой, включавшей малые дозы оланзапина, – в 24 (77%) (р = 0,027). Нежелательные явления, ассоциированные с приемом оланзапина, встречались достаточно часто (седация 97%, набор веса 76%), но были выражены незначительно (< III степени). При проведении опроса пациентов режим с включением оланзапина для продолжения лечения предпочли 30/31 (97%) больных, лишь 1 больной не отдал предпочтения ни одному из режимов. Промежуточный анализ результатов исследования свидетельствует, что добавление малых доз оланзапина значимо увеличивает эффективность профилактики ТИР у пациентов педиатрического профиля, получающих высокоэметогенную химиотерапию, хорошо переносится, безопасен и предпочитается подавляющим большинством больных. Необходимо продолжение исследования до достижения планового числа включенных пациентов для окончательного анализа.

chemotherapy-induced nausea and vomitingantiemetic therapychildrenadolescentsolanzapineantiemeticsemetogenicityтошнота и рвотаиндуцированные цитостатической терапиейпротиворвотная терапиядетиподросткиоланзапинантиэметикиэметогенность1. Paw Cho Sing E., Robinson P.D., Flank J., Holdsworth М., Thackray J., Freedman J., et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatr Blood Cancer 2019; 66 (5): e27646. DOI:10.1002/pbc.27646Paw Cho Sing E., Robinson P.D., Flank J., Holdsworth М., Thackray J., Freedman J., et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatr Blood Cancer 2019; 66 (5): e27646. DOI:10.1002/pbc.276462. Patel P., Robinson P.D., Thackray J., Flank J., Holdsworth M.T., Gibson P., et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer 2017; 64 (10). DOI:10.1002/pbc.26542Patel P., Robinson P.D., Thackray J., Flank J., Holdsworth M.T., Gibson P., et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer 2017; 64 (10). DOI:10.1002/pbc.265423. Dupuis L.L., Robinson P.D., Boodhan S., Holdsworth М., Portwine С., Gibson Р., et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 2014; 61 (8): 1506–12. DOI:10.1002/pbc.25063Dupuis L.L., Robinson P.D., Boodhan S., Holdsworth М., Portwine С., Gibson Р., et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 2014; 61 (8): 1506–12. DOI:10.1002/pbc.250634. Flank J., Robinson P.D., Holdsworth M., Phillips R., Portwine С., Gibson Р., et al. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer 2016; 63 (7): 1144–51. DOI:10.1002/pbc.25955Flank J., Robinson P.D., Holdsworth M., Phillips R., Portwine С., Gibson Р., et al. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer 2016; 63 (7): 1144–51. DOI:10.1002/pbc.259555. Hyoung J.K., Susan L., Arlane T., DiCristina С., Green S., Zwaan С.М. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet 2015; 16 (4): 385–94. DOI:10.1016/S1470-2045(15)70061-6Hyoung J.K., Susan L., Arlane T., DiCristina С., Green S., Zwaan С.М. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet 2015; 16 (4): 385–94. DOI:10.1016/S1470-2045(15)70061-66. Sameer B., Atul B., Bivas B., Dhawan D., Paul R., Sreenivas V. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Supportive Care Cancer 2015; 23: 3229–37. DOI:10.1007/s00520-015-2714-9Sameer B., Atul B., Bivas B., Dhawan D., Paul R., Sreenivas V. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Supportive Care Cancer 2015; 23: 3229–37. DOI:10.1007/s00520-015-2714-97. Рабаева Л.Л., Жуков Н.В. Тошнота и рвота на фоне высокоэметогенной химиотерапии у детей и подростков. Скрытая проблема 2022; (2): 46–53. DOI:10/21682/2311-1267-2022-9-2-46-53Рабаева Л.Л., Жуков Н.В. Тошнота и рвота на фоне высокоэметогенной химиотерапии у детей и подростков. Скрытая проблема 2022; (2): 46–53. DOI:10/21682/2311-1267-2022-9-2-46-538. Жуков Н.В., Рабаева Л.Л. Эффективность стандартной профилактики тошноты и рвоты у детей, получающих высокоэметогенную химиотерапию: данные реальной клинической практики. Педиатрия. Журнал им. Г.Н. Сперанского 2022; 101 (4): 172–9. DOI:10.24110/0031-403X-2022-101-4-172-179Жуков Н.В., Рабаева Л.Л. Эффективность стандартной профилактики тошноты и рвоты у детей, получающих высокоэметогенную химиотерапию: данные реальной клинической практики. Педиатрия. Журнал им. Г.Н. Сперанского 2022; 101 (4): 172–9. DOI:10.24110/0031-403X-2022-101-4-172-1799. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck К., DeLapp N.W., Cohen M.L. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001; 430 (23): 341–9. DOI:10.1016/S0014-2999(01)01399-1Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck К., DeLapp N.W., Cohen M.L. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001; 430 (23): 341–9. DOI:10.1016/S0014-2999(01)01399-110. Srivastava M., Brito-Dellan N., Davis M.P., Leach М., Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25 (6): 578–82. DOI:10.1016/S0885-3924(03)00143-XSrivastava M., Brito-Dellan N., Davis M.P., Leach М., Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25 (6): 578–82. DOI:10.1016/S0885-3924(03)00143-X11. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9: 188–95.Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9: 188–95.12. Navari R.M., Qin R., Ruddy K.J., Liu Н., Powell S.F., Bajaj М., et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375 (2): 134–42. DOI:10.1056/NEJMoa1515725Navari R.M., Qin R., Ruddy K.J., Liu Н., Powell S.F., Bajaj М., et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375 (2): 134–42. DOI:10.1056/NEJMoa151572513. Zhang Z., Zhang Y., Chen G., Hong S., Yang Y., Fang W., et al. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor AntagonistBased Triple Regimens in Preventing ChemotherapyInduced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist 2018; 23 (5): 603–16.Zhang Z., Zhang Y., Chen G., Hong S., Yang Y., Fang W., et al. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor AntagonistBased Triple Regimens in Preventing ChemotherapyInduced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist 2018; 23 (5): 603–16.14. Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., Ma G.J., Eldridge К., Hipple А., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97 (12): 3090–8. DOI:10.1002/cncr.11433Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., Ma G.J., Eldridge К., Hipple А., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97 (12): 3090–8. DOI:10.1002/cncr.1143315. Hesketh P.J., Kris M.G., Basch E., Bohlke К., Barbour S.Y., ClarkSnow R.A., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35 (28): 3240–61. DOI:10.1200/JCO.2017.74.4789Hesketh P.J., Kris M.G., Basch E., Bohlke К., Barbour S.Y., ClarkSnow R.A., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35 (28): 3240–61. DOI:10.1200/JCO.2017.74.478916. Basch E., Prestrud A.A., Hesketh P.J., Kris M.G., Feyer Р.С., Somerfield M.R., et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 29 (31): 4189–98.Basch E., Prestrud A.A., Hesketh P.J., Kris M.G., Feyer Р.С., Somerfield M.R., et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 29 (31): 4189–98.17. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5: 32–43.Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5: 32–43.18. Roila F., Molassiotis A., Herrstedt J., Aapro М., Gralla R.J., Bruera E., et al. 2016 MASCC and ESMO guideline update for the prvention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (suppl 5): v119–33. DOI:10.1093/annonc/mdw270Roila F., Molassiotis A., Herrstedt J., Aapro М., Gralla R.J., Bruera E., et al. 2016 MASCC and ESMO guideline update for the prvention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (suppl 5): v119–33. DOI:10.1093/annonc/mdw27019. Hashimoto H., Abe M., Tokuyama O., Mizutani Н., Uchitomi Y., Yamaguchi Т., et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21 (2): 242–9. DOI:10.1016/S1470-2045(19)30678-3Hashimoto H., Abe M., Tokuyama O., Mizutani Н., Uchitomi Y., Yamaguchi Т., et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21 (2): 242–9. DOI:10.1016/S1470-2045(19)30678-320. Samsel C., Kearney J., Meadows A.L., Abrams A., Hirst J.M., Muriel A.C. Olanzapine for chemotherapy-induced nausea:Lessons learned from child and adolescent psychiatry. Pediatr Blood Cancer 2018; 65 (10): e27289. DOI:10.1002/pbc.27289.Samsel C., Kearney J., Meadows A.L., Abrams A., Hirst J.M., Muriel A.C. Olanzapine for chemotherapy-induced nausea:Lessons learned from child and adolescent psychiatry. Pediatr Blood Cancer 2018; 65 (10): e27289. DOI:10.1002/pbc.27289.21. Flank J., Sung L., Dvorak C.C., Spettigue W., Dupuis L.L. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf 2014; 37 (10): 791–804. DOI:10.1007/s40264-014-0219-yFlank J., Sung L., Dvorak C.C., Spettigue W., Dupuis L.L. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf 2014; 37 (10): 791–804. DOI:10.1007/s40264-014-0219-y22. Flank J., Thackray J., Nielson D., August A., Schechter T., Alexander S., et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in: A retrospective, multi-center review. Pediatr Blood Cancer 2015; 62: 496–501.Flank J., Thackray J., Nielson D., August A., Schechter T., Alexander S., et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in: A retrospective, multi-center review. Pediatr Blood Cancer 2015; 62: 496–501.23. Radhakrishnan V., Pai V., Rajaraman S., Mehra N., Ganesan T., Dhanushkodi M., et al. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial. Pediatr Blood Cancer 2020: e28532. DOI:10.1002/pbc.28532Radhakrishnan V., Pai V., Rajaraman S., Mehra N., Ganesan T., Dhanushkodi M., et al. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial. Pediatr Blood Cancer 2020: e28532. DOI:10.1002/pbc.2853224. Naik R.D., Sreenivas V., Singh V., Pillai A.S., Dhawan D., Bakhshi S. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. J Clin Oncol 2020; 38 (32): 3785–93. DOI:10.1200/JCO.20.00871Naik R.D., Sreenivas V., Singh V., Pillai A.S., Dhawan D., Bakhshi S. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. J Clin Oncol 2020; 38 (32): 3785–93. DOI:10.1200/JCO.20.0087125. Yoodee J., Permsuwan U., Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2017; 112: 113–25.Yoodee J., Permsuwan U., Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2017; 112: 113–25.26. Navari R.M., Qin R., Ruddy K.J., Liu H., Powell S.F., Bajaj М., et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016; 375 (2): 134–42.Navari R.M., Qin R., Ruddy K.J., Liu H., Powell S.F., Bajaj М., et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016; 375 (2): 134–42.27. Hirsch L., Yang J., Bresee L., Jette N., Patten S., Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf 2017; 40 (9): 771–81.Hirsch L., Yang J., Bresee L., Jette N., Patten S., Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf 2017; 40 (9): 771–81.28. Zhang Y., Liu Y., Su Y., You Y., Ma Y., Yang G., et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry 2017; 17 (1): 373. DOI:10.1186/s12888-017-1539-0Zhang Y., Liu Y., Su Y., You Y., Ma Y., Yang G., et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry 2017; 17 (1): 373. DOI:10.1186/s12888-017-1539-029. Goodman & Gilman's pharmacological basis of therapeutics. Goodman L.S., Brunton L.L., Chabner B.A., Knollmann B.C. (eds.). 12th ed. N.-Y.: McGrawHill; 2011. 2084 p.Goodman & Gilman's pharmacological basis of therapeutics. Goodman L.S., Brunton L.L., Chabner B.A., Knollmann B.C. (eds.). 12th ed. N.-Y.: McGrawHill; 2011. 2084 p.30. Samsel C., Kearney J., Meadows A.L., Abrams A., Hirst J.M., Muriel A.C. Olanzapine for chemotherapy-induced nausea:Lessons learned from child and adolescent psychiatry. Pediatr Blood Cancer 2018; 65 (10): e27289. DOI:10.1002/pbc.27289Samsel C., Kearney J., Meadows A.L., Abrams A., Hirst J.M., Muriel A.C. Olanzapine for chemotherapy-induced nausea:Lessons learned from child and adolescent psychiatry. Pediatr Blood Cancer 2018; 65 (10): e27289. DOI:10.1002/pbc.2728931. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute. [Internet]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdfCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute. [Internet]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf32. Silveira A., Sequeira T., Gonçalves J., Lopes Ferreira P. Patient reported outcomes in oncology: changing perspectives-a systematic review. Health Qual Life Outcomes 2022; 20 (1): 82. DOI:10.1186/s12955-022-01987-xSilveira A., Sequeira T., Gonçalves J., Lopes Ferreira P. Patient reported outcomes in oncology: changing perspectives-a systematic review. Health Qual Life Outcomes 2022; 20 (1): 82. DOI:10.1186/s12955-022-01987-x33. Teixeira M.M., Borges F.C., Ferreira P.S., Rocha J., Sepodes B., Torre C. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Front Med (Lausanne) 2022; 9: 968272. DOI:10.3389/fmed.2022.968272Teixeira M.M., Borges F.C., Ferreira P.S., Rocha J., Sepodes B., Torre C. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Front Med (Lausanne) 2022; 9: 968272. DOI:10.3389/fmed.2022.968272